Palvella Therapeutics Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, Palvella Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $230.53. The average 1-year stock price forecast is 46.12% higher than the current stock price, while the lowest is $205 (+29.94%) and the highest is $270 (+71.14%).

Price Target: $230.53 (+46.12%)

Analyst Consensus: Strong Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$205	$230.53	$232	$270
Change	+29.94%	+46.12%	+47.05%	+71.14%

Analyst Ratings

The average analyst rating for Palvella Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart

Rating	Feb '26	Mar '26	Apr '26	May '26	Jun '26	Jul '26
Strong Buy	15	15	15	16	15	15
Buy	0	0	0	0	0	0
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	15	15	15	16	15	15

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Andrew Fein H.C. Wainwright	H.C. Wainwright	Buy Maintains $270	Buy	Maintains	$270	+71.14%	Aug 5, 2026
Trevor Allred Oppenheimer	Oppenheimer	Buy Reiterates $210	Buy	Reiterates	$210	+33.11%	Aug 5, 2026
Danielle Brill Truist Financial	Truist Financial	Buy Reiterates $210 → $207	Buy	Reiterates	$210 → $207	+31.20%	Aug 5, 2026
Sam Slutsky LifeSci Capital	LifeSci Capital	Buy Maintains $225 → $236	Buy	Maintains	$225 → $236	+49.58%	Aug 5, 2026
Whitney Ijem Canaccord Genuity	Canaccord Genuity	Buy Maintains $227 → $232	Buy	Maintains	$227 → $232	+47.05%	Aug 5, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

Revenue Next Year

29.03M

EPS This Year

-6.25

from -3.71

EPS Next Year

-7.40

from -6.25

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	-	-	-	-	-
Operating Income	-18.04M	-11.87M	-14.10M	-38.60M	-91.23M
Net Income	-27.55M	18.69M	-17.43M	-41.72M	-90.98M
EPS	-	-	-	-3.71	-6.25
Free Cash Flow	-	-9.96M	-5.43M	-18.63M	-89.79M
No. Analysts	-	-	-	-	14

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	n/a
Avg	n/a
Low	n/a

Revenue Growth

Chart

Revenue Growth	2027	2028
High	-
Avg	-
Low	-

EPS Forecast

Chart

EPS	2026	2027	2028
High	-3.95
Avg	-6.25
Low	-7.84

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-